Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 501–600 of 678
Salmanpour, M. R., Piri, S. M., Mehrnia, S. S., Shariftabrizi, A., Allahmoradi, M., Manem, V. S., Rahmim, A., & Hacihaliloglu, I. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01817-8 · Cited by 5
“…poorly differentiated tumors are inversely related to tumor nodule size and directly related to alpha-fetoprotein levels [86]. moderately to poorly differentiated HCC tissue, and are more frequently associated with portal vein invasion and intrahepatic metastasis than the simple nodular type [78].”
InfluentialNakajima, K., Kamiyama, N., Sugimoto, K., Hashimoto, H., & Itoi, T. (2026) · Journal of Medical Ultrasonics · doi:10.1007/s10396-025-01598-1 · Cited by 1
Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71640 · Cited by 1
“HCC was diagnosed based on guidelines established by the Japan Society of Hepatology (JSH) [5] and confirmed by use of combinations of clinical, radiological, and/or pathological findings.”
Self-citationEl‐Kassas, M., Khalifa, R., Kohla, M., Marwan, E., Abdelmalek, M. O., & Shousha, H. I. (2026) · Liver International · doi:10.1111/liv.70595 · Cited by 2
“The HCC Practice Manual of the Japan Society of Hepatology recommends combined use of AFP, AFP L3, and PIVKA II or DCP using cut offs of 10 ng/mL, 10%, and 40 mAU/ mL, respectively, to support surveillance, diagnosis, treatment assessment, and recurrence monitoring [89].”
Nguyen, K. V., Matsui, K., Kosaka, H., Matsushima, H., Yamamoto, H., Kiguchi, G., Ohigashi, T., Lai, T. T., Duong, H. H., Inoue, K., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70152 · Cited by 1
Self-citationShi, F., Peng, Z., Lian, S., Mai, Q., Xia, D., Li, Q., Wang, M., Chen, S., Mei, J., Han, G., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02406-4 · Cited by 1
“In Asian countries, local HAIC has progressively gained acceptance as an alternative treat-ment, endorsed by the Chinese and Japan Society of Hepatology guideline for advanced HCC [12, 13].”
Luu, V. D., Tân, Đ. Đ., Thông, P. M., Khang, L. V., Dung, L. T., Bỉnh, L. T., Trang, N. N., Cương, N. N., Luan, N. D., le Lam, N., et al. (2026) · Frontiers in Radiology · doi:10.3389/fradi.2026.1763042 · Cited by 1
Efficacy and safety of carbon-ion radiotherapy for large hepatocellular carcinoma (diameter ≥ 10 cm)
Hayashi, K., Suzuki, O., Ichise, K., Uchida, H., Nagano, F., Hasegawa, A., Shimizu, S., Fujimoto, J., & Ogawa, K. (2026) · BMC Cancer · doi:10.1186/s12885-026-16096-x · Cited by 1
“When HCC is confined to the liver and liver function is preserved, surgery or radiofrequency ablation (RFA) is the first choice for local therapy [2, 3].”
Yang, S., Zhang, S., & Gu, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1811934 · Cited by 1
“Clinical data from HCC-PVTT patients treated with either combined TACE-HAIC therapy or TACE alone at the Af fi liated Hospital of Xuzhou Medical University between January 2019 and September 2023 were collected.”
InfluentialTakenaga, T., Hanaoka, S., Nomura, Y., Kikuchi, T., Yoshikawa, T., & Abe, O. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-026-02080-1 · Cited by 1
Kudo, M., Abou-Alfa, G. K., Ren, Z., Heo, J., Lencioni, R., Arai, Y., Bouattour, M., Gonzalez-Carmona, M. A., Guo, Y., Ai-Bing, X. U., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00278-0 · Cited by 6
Self-citationLi, X., Cai, H., 王, 承., YingXue, Q., Yu, T., Zhang, Q., Liu, H., Luo, N., Chen, J., Cheng, S., et al. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45555 · Cited by 1
李, 玮. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12111521 · Cited by 1
Current Status of Imaging Diagnosis and Treatment of Subcentimeter Hepatocellular Carcinoma
Huang, P., Xiao, Y., Zhou, C., Wu, F., Yang, C., & Zeng, M. (2023) · Current Chinese Science · doi:10.2174/2210298103666230410104223 · Cited by 1
Tan, Z., Wu, D., Guo, J., Wang, H., & Zhang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1201381 · Cited by 1
Gurtatta, R. S., Whalen, S. E., & Ray, C. E. (2024) · Seminars in Interventional Radiology · doi:10.1055/s-0043-1778660 · Cited by 1
Tang, S., Gao, Y., Yan, X., Zhi, W., & Yue, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431069 · Cited by 1
Promsorn, P., Yamaguchi, T., Kosaka, H., Aoi, K., Yoshida, K., Matsushima, H., Matsui, K., Shimoda, S., Kaibori, M., & Naganuma, M. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2761 · Cited by 2
“TACE is recommended by a number of clinical practice guidelines worldwide for patients with intermediate‑stage HCC: American Association for the Study of Liver Disease (AASLD), European Association for the Study of the Liver (EASL), Japan Society of Hepatology (JSH) (4,12,13).”
BackgroundMethodIshikawa, T., Sato, R., JIMBO, R., Kobayashi, Y., Sato, T., Iwanaga, A., Sano, T., Yokoyama, J., & Honma, T. (2024) · In Vivo · doi:10.21873/invivo.13721 · Cited by 1
“In the 2021 Guidelines for the Treatment of Liver Cancer (8), the recommended treatments for HCC with vascular invasion are systemic pharmacotherapy, and TACE, with no recommendations for radiotherapy.”
InfluentialIntermediate hepatocellular carcinoma: new horizons and prospects for our patients
Prinzi, F. L., Rossari, F., Silletta, M., Foti, S., Camera, S., Vitiello, F., Amadeo, E., COBELLI, F. D., Aldrighetti, L. A., Rimini, M., et al. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2422367 · Cited by 1
Gao, J., Lu, Z., Liang, W., Zhang, J., Qin, S., Huang, J., Gong, W., & Xiang, B. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2431348 · Cited by 1
Liu, W., Zhang, K., Chen, S., Wang, X., & Yu, W. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0393 · Cited by 5
Zeng, Q., Zhou, Z., Zhang, J., Cai, R., Yang, H., Chen, P., & Li, L. (2025) · BMC Cancer · doi:10.1186/s12885-024-13390-4 · Cited by 2
Rinka, K., Kioka, K., Amano, Y., Nakai, T., Kawasaki, Y., & Kawada, N. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05040-5 · Cited by 1
Chen, M., Ren, C., Wang, M., Yu, M., Wu, B., Zhuang, B., Jin, J., Zhang, Y. M., & Yu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1450333 · Cited by 1
Fujita, K., Takuma, K., Oura, K., Tadokoro, T., Morishita, A., Himoto, T., & Kobara, H. (2025) · Clinical and Translational Science · doi:10.1111/cts.70182 · Cited by 1
Hayashi, M., Takahata, Y., Abe, N., Sugaya, T., Fujita, M., Abe, K., Takahashi, A., & Ohira, H. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf041 · Cited by 1
Kwon, J. H., Jwa, E., Lee, J. W., Tak, E., & Hwang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-92500-z · Cited by 2
Zhou, S., Song, C., Liu, P., Ju, S., & Wang, Y. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112057 · Cited by 1
Xu, W., Ding, X., Xu, Y., Zhang, Y., Xu, H., Guo, L., & Li, L. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s481334 · Cited by 1
Matono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70011 · Cited by 2
Self-citationAkutsu, N., Kawakami, Y., Numata, Y., Hirano, T., Wagatsuma, K., Ishigami, K., Sasaki, S., & Nakase, H. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01669-7 · Cited by 1
“At present, for patients with extrahepatic spread, systemic therapy is the only recommended treatment [38].”
BackgroundChung, J. W. (2022) · Radiology · doi:10.1148/radiol.212826 · Cited by 1
Sugimoto, R., Motomura, K., Satoh, T., Tanaka, Y., Yamashita, S., Higuchi, N., Koyanagi, T., Nakamura, T., Tanaka, M., Azuma, Y., et al. (2023) · Preprints.org · doi:10.20944/preprints202310.1682.v1 · Cited by 1
The New Perspectives Journal of Medicine
(2024) · The New Perspectives Journal of Medicine · doi:10.5582/npjm.2023.01227
Analysis of Adverse Drug Reactions with Oxaliplatin-Based Hepatic Arterial Infusion ChemotherapyPreprint
Lu, Y., Zhang, Z., & Ye, Y. (2024) · Preprints.org · doi:10.20944/preprints202407.1758.v1
HOX Gene Family Defines Tumor Microenvironment and Drug Sensitive in Hepatocellular CarcinomaPreprint
Li, D., Yu, T., Zeng, Z. R., Wu, J., Han, J., & Zhou, B. (2021) · Research Square · doi:10.21203/rs.3.rs-806092/v1
La Devoción a la Virgen de los Dolores de Requena y su Asociación fundada en 1893
Marrades, S. C. (2001) · Oleana: Cuadernos de Cultura Comarcal
Staring a project-management organization - a utility perspective
Santoro, P., & Nadeau, L. (1988) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Saeki, I. (2021) · Yamaguchi Medical Journal · doi:10.2342/ymj.70.157
Pu, Z., Liu, Z., Jiang, C., Inoue, K., Ruan, Z., Zhu, L., Kikuchi, H., Matsui, A., Huang, P., & Duda, D. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.23.497362
Lu, H.-Z., Mai, R., Wang, X.-B., Liang, R., Lin, Y., Chen, J., Wu, F., Xiang, B., Cheng, S., Li, L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2013785/v1
Mohamed, E. H., Meghezel, E.-Z. M., & Abokresha, S. (2022) · NILES Journal forGeriatric and Gerontology/NILES Journal for Geriatric and Gerontology · doi:10.21608/niles.2022.157385.1070
“65 Disease recommendations, which consisted of arterial hyper enhancement with washout seen on portal or delayed-phase images[11]”
BackgroundOutcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib
Nakagawa, D., Komatsu, S., Yano, Y., Kido, M., Kuramitsu, K., Yamamoto, A., Omiya, S., SHIMURA, Y., Goto, T., Yanagimoto, H., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16234
Ueno, M., Kayahara, T., Takabatake, H., Morimoto, Y., & Mizuno, M. (2023) · Kanzo · doi:10.2957/kanzo.64.122
Wang, S.-Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0082
Xing, X. Y. L. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.48.007690
Ohira, M., Kobayashi, T., Hamaoka, M., Abe, T., Onoe, T., Inoue, M., Honmyo, N., Oishi, K., & Ohdan, H. (2023) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-023-03057-2
Publications from Juntendo University Graduate School of Medicine, 2021 [2/6]
(2023) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.jmj23-69.4-pl
Ichikawa, S., Motosugi, U., Sawai, Y., Ishida, H., Imai, Y., Kozaka, K., Tsurusaki, M., Sofue, K., Murakami, T., Kawai, N., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13964
“26 The HEPATOLOGY RESEARCH ICHIKAWA ET AL .”
BackgroundSelf-citationAdvances in the Combined Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
杜, 常. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141059
Liu, W., Zhang, K., Chen, S., Wang, X., & Yu, W. (2024) · Research Square · doi:10.21203/rs.3.rs-3855581/v1
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
Johira, Y., Nakahara, T., Yamaoka, K., Fujii, Y., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., Kawaoka, T., Miki, D., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002720
“Liver resection is a curative treatment mainly performed in patients with Barcelona Clinic Liver Cancer 0/A stage HCC in American, European, and Japanese guidelines [4–6], although the high rate of postoperative recurrence wors-ens their prognosis [7,8].”
Background陈, 琪. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441291
Huang, H., Chang, T., Canseco, L. M., Wu, F., & Lu, S. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12838
Chen, Z., Li, L., Kudo, M., Lee, H., Graves, N., Chow, P. K. H., & Asia-Pacific Hepatocellular Carcinoma Trials Group (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4834019
Self-citationShigematsu, Y., Kanda, H., Takahashi, Y., Takeuchi, K., & Inamura, K. (2024) · Research Square · doi:10.21203/rs.3.rs-4418866/v1
Yang, K., Wu, K., Lei, Z., Liu, T., Zhang, X., Li, J., Yang, K., Peng, Q., Lin, T. Y., Liu, C., et al. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.85 · Cited by 1
Jiang, H., & Tian, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95223-1.00009-6
Lai, Z., Xu, Y.-J., Chen, H., Kan, A., Wu, Z., Li, Q., Lu, M.-Q., Wei, W., Zhang, Y., Chen, M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4894780
Ramaswamy, A., Shukla, A., Engineer, R. Z., Sundaram, S., Srinivas, S., Kulkarni, S. S., Patkar, S., Baijal, S. S., Kale, A. P., Kapoor, A., et al. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0044-1788569
“Out of various classi fi cation systems for PVTT, the Vp classi fi cation system from the Liver Cancer Study Group of Japan is the most commonly used and the knowledge of the location of PVTT impacts prognosis and therapeutic options.”
Advances in Exosomes in the Early Diagnosis of Digestive System Tumor
谭, 聪. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482180
Ding, W., Tian, X., Xu, H., Cheng, Z. G., Zheng, L., Liu, F., Yu, J., & Liang, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4750918/v1
Zhu, Y.-B., Qin, J.-Y., Zhang, T., Zhang, W., & Ling, Q. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i10.3312
Abe, S., Inagaki, Y., Kokudo, T., Miyata, A., Nishioka, Y., Ichida, A., Kaneko, J., Akamatsu, N., Kawaguchi, Y., & Hasegawa, K. (2024) · Hepatology Research · doi:10.1111/hepr.14120 · Cited by 1
Self-citation郭, 臣. (2024) · Hans Journal of Surgery · doi:10.12677/hjs.2024.134011
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy
Yıldırım, E. Ç., & Ergün, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i12.4757
Yamamoto, M., Morishima, K., Endo, K., Shimodaira, K., Kimura, Y., Aoki, Y., Taguchi, M., Sasanuma, H., Sakuma, Y., Watanabe, S., et al. (2024) · Cureus · doi:10.7759/cureus.73864
Pagani, M., Tasca, C., Vincenti, R. D., & Fedi, M. (2024) · Cureus · doi:10.7759/cureus.74585
Role of immunotherapy in managing cancers prior to liver transplantation
Bredin, P., Galvin, Z., & O'Kane, G. M. (2024) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001187
Hepatic artery infusion chemotherapy: A resurgence
Fung, A. K. Y., & Chok, K. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.99612
“There is clinical evidence to support favourable outcomes for HAIC[8-11], and HAIC is recommended as the first-line treatment for advanced HCC in Korean[12] and Japanese[13] guidelines.”
Sun, Q., Wu, Z., Yin, X., Li, F., & Liu, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483949
Pei, W., Jiao, B., Chen, Z., Zeng, J., Fu, Y., Liang, Z., Sun, B., Ruan, J., & Zhang, S. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100581
Current impact in the treatment of advanced hepatocellular carcinoma: The challenge remains
de Mattos, Â. A., Tovo, C. V., Bombassaro, I., & Ferreira, L. F. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.102932
Combination Therapies for Primary Liver Cancer
Chao, C. H., Kim, B. J., & Liu, Y. (2024) · Springer eBooks · doi:10.1007/978-3-030-51192-0_84-1
A Case of Hepatocellular Carcinoma in a Patient with Idiopathic Forearm Arteriovenous Fistula
Takada, S., Yata, Y., Ishizu, H., Inoue, Y., Kuroda, T., Ikeda, S., Jogo, A., Yamamoto, A., Higashiyama, H., & Kawada, N. (2025) · Case Reports in Gastroenterology · doi:10.1159/000544101
Takaya, H., Namisaki, T., Komeda, Y., Kinoshita, H., Nishimura, N., Tsuji, Y., Sato, S., Nishimura, N., Saito, K., Aizawa, S., et al. (2025) · JGH Open · doi:10.1002/jgh3.70145
Thanh, L. H., Manh, K. N., & Quang, H. N. (2025) · Health Science Reports · doi:10.1002/hsr2.70655
“The main causes are usually viral hepatitis B, hepatitis C, alcoholic liver disease, and aflatoxin B1 exposure [2 – 4].”
Liu, Z., Shi, J., Zhang, M., & Dang, S. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i4.251
Tan, Y. H., Li, P., Liu, H., Zhu, J., & Wu, Q. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s513695 · Cited by 1
Ngô, T. M., Quang, H. D., & Hữu, T. H. (2025) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v549i3.13973
“…đoán hình ảnh như cắt lớp vi tính và cộng hưởng từ, các dấu ấn sinh học trong máu như Alpha-fetoprotein (AFP), AFP-L3, Des-γ - carboxy prothrombin đóng vai trò quan trọng trong chẩn đoán UTBMTBG tuy nhiên vẫn còn nhiều bệnh nhân (BN) không điển hình, cần phải sinh thiết gan để chẩn đoán [2], [3].”
Hayashi, M., Abe, K., Sugaya, T., Abe, N., Takahata, Y., Fujita, M., & Ohira, H. (2025) · Oncology · doi:10.1159/000546334
Duong, H., Ngo, M., Dao, T., Hoang, T., Nguyen, U., & Ho, T. H. (2025) · Diagnostics · doi:10.3390/diagnostics15111364
“…techniques such as ultrasound, CT scans, and MRI, alongside serum biomarkers like AFP and PIVKA II, are commonly used but lack the sensitivity and specificity needed for detecting early-stage HCC. Liver biopsies, while more definitive, carry procedural risks, including bleeding and infection [4–6].”
Shen, X., Shao, T., Yu, J., & Zhang, Z. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s530550
Chen, X., Wang, C., Yuanjie, T., Sun, H., Liu, H., Lin, C., & Yuan, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-12858-y · Cited by 1
“Current clinical guidelines advocate that non-surgical candidates consider therapeutic modalities such as transcatheter arterial chemoembolization (TACE), ablation, or radiotherapy 2,3 .”
Kokudo, T., Halkic, N., & Kokudo, N. (2025) · Global Health & Medicine · doi:10.35772/ghm.2025.01088
Self-citationOhama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2025) · Oncology · doi:10.1159/000547353
“…treatment for unresectable advanced HCC cases with good performance status (PS) and good liver function classified as Child-Pugh (CP) class A that are not considered suitable for surgical resection, liver transplantation, locoregional therapy, or transarterial chemo-embolization (TACE) [11].”
Self-citationShirakawa, S., Yanai, T., & Kawakami, K. (2025) · Oncology · doi:10.1159/000547883 · Cited by 1
“This category includes varying tumor burdens and responses to TACE [4].”
InfluentialOncologic liver transplantation: Transplant oncology
Hibi, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00010-1
Matsuda, M., Yoshiya, S., Kawada, I., Nakamura, S., Tada, K., Ito, K., Koso, H., Kuroda, Y., Yoshizumi, F., Iwaki, K., et al. (2025) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjaf679
“Treatment options for recurrent HCC include resection, local therapy, TACE, chemotherapy and liver transplantation [10–12].”
Zhao, J., Fu, G., Wang, Y., & Yang, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-47502-w
“AFP and tumor number have been validated as independent risk factors for treatment response following TACE in HCC patients across multiple studies 31–33 , and remain incorporated parameters in established classical HCC prognostic scoring systems 22 .”
Takada, H., Osawa, L., Komiyama, Y., Muraoka, M., Suzuki, Y., Sato, M., Kobayashi, S., Yoshida, T., Takano, S., Maekawa, S., et al. (2025) · Oncology · doi:10.1159/000548667
“The latest guidelines in Japan recommend AB therapy and tremelimumab plus durvalumab therapy as the first-line treatment for patients indicated for combination immunotherapy, and SOR, lenvatinib (LEN), or durvalumab for those who are not [4–6].”
Takaura, K., Tsuchiya, K., Taguchi, M., Tokunaga, Y., Uchihara, N., Kimura, S., Tanaka, Y., Yagita, J., Miyamoto, H., Keitoku, T., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334712
“In the guidelines, treatment options for early-stage HCC within the Milan criteria (largest HCC diameter ≤3 cm and ≤3 HCC nodules) include radiofrequency ablation (RFA), hepatic resection, and liver transplantation [6–8].”
Self-citationHuang, H., Pan, K.-C., Chang, T.-S., Chen, S., Lu, H.-J., & Lu, S. (2025) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100804
Impact of laparoscopic approach on volumetric and functional liver recovery in advanced hepatectomy
Okura, K., Yoh, T., Ogiso, S., Yoshimura, K., Kanda, S., Nishino, H., Okuno, M., Nishio, T., Uchida, Y., Ishii, T., et al. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.09.181
Self-citationXue, J., Gu, Y., Li, J., Zhang, J., Bian, T., Zhou, Z., & Gao, Y. (2025) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/cjgh/4859487
“However, the options for managing HCC in decompensated cirrhosis are limited, often leaving liver transplantation as the only specifc treatment [7, 8], which is restricted by criteria and donor shortages, highlighting the need for alternative treatments for advanced liver disease.”
Kamiyama, N., Sugimoto, K., Nakahara, R., Kakegawa, T., & Itoi, T. (2025) · Choonpa Igaku · doi:10.3179/jjmu.jjmu.k.38
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.